Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

Regulus reports preliminary interim data from mouse chronic toxicity study of RGLS-4326

Jan. 7, 2019

FDA accepts IND for phase Ib study of DM-199 for diabetes-related CKD

Jan. 3, 2019

Failure of AMPK caused by multiple uremic factors is a key mechanism of energy depletion in CKD

Jan. 3, 2019

Perlara and Rambam Medical Center enter APOL1 kidney disease partnership

Dec. 28, 2018

First patient dosed in pivotal phase III PROTECT study of sparsentan

Dec. 28, 2018

Antiviral response damages kidney in bacterial sepsis

Dec. 14, 2018

New phase IIb trial investigates efficacy of male contraceptive gel

Nov. 29, 2018

Dimerix begins dosing in phase II trials of DMX-200 for kidney disease

Nov. 23, 2018

Nash Pharmaceuticals reports data on NP-135 in mouse model of kidney fibrosis

Nov. 20, 2018

Calliditas begins phase III study of Nefecon in IgA nephropathy

Nov. 14, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Latus Bio series A financing supports early-stage programs
BioWorld Science
Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the...